Deruxtecan Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden

Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.

Indications

By Deruxtecan Preparation Trastuzumab deruxtecan drug is approved by the FDA for the treatment of patients with any HER2-positive advanced solid tumour (e.g., breast, gastric, and GOJ adenocarcinomas) and only after the patient has previously received other advanced treatments.

Mechanism of action

Deruxtecan is attached to the antibody by a peptide linker. After trastuzumab deruxtecan binds to HER2 found on malignant cells, it is internalized and linker cleavage occurs through the actions of lysosomal enzymes. After it is released through cleavage, DXd causes targeted DNA damage and apoptosis in cancer cells, due to the ability to cross cell membranes.

Nebenwirkungen

The most common side effects of Deruxtecan (Trastuzumab deruxtecan) include: nausea, vomiting, diarrhoea, fatigue, hair loss, increased risk of infections (low white blood cell counts, red blood cell counts, and platelet counts), breathlessness, coughing, headache, bone or muscle pain, mouth ulcers, loss of appetite, weight loss, heart problems, liver or skin changes, low potassium levels. All of these side effects may not always occur at the same time and will vary from person to person. Serious adverse reactions include: interstitial lung disease/pneumonia, serious impairment of heart function and allergic reactions. Special care should be taken to contact your doctor in case of any serious adverse reactions.

Deruxtecan Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Deruxtecan Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Xilinglab Co., Ltd.	+8618381337976	bd@xilinglab.com	China	86	58
Wuhan Jingkang en Biomedical Technology Co., Ltd	+8613720134139	orders@jknbiochem.com	China	5221	58
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	32951	60
Jinan Carbotang Biotech Co.,Ltd.	+8615866703830	figo.gao@foxmail.com	China	8497	58
Chengdu Pukang Biotechnology Co., Ltd	028-82550498	export@pu-kang.com	CHINA	210	58
BOC Sciences	+1-631-485-4226	inquiry@bocsci.com	United States	19553	58
TargetMol Chemicals Inc.	+1-781-999-5354 +1-00000000000	marketing@targetmol.com	United States	32070	58
Career Henan Chemica Co	+86-0371-86658258 +8613203830695	laboratory@coreychem.com	China	30241	58
Finetech Industry Limited	+86-27-87465837 +8618971612321	info@finetechnology-ind.com	China	9640	58
Shenzhen Shengda Pharma Limited	755-85269922 +8613424394241	sales@shengdapharm.com	CHINA	310	58

---

• Deruxtecan analog
• Glycinamide, N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]glycylglycyl-L-phenylalanyl-N-[[2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]amino]-2-oxoethoxy]methyl]-
• MC-GGFG-Exetecan
• Deruxtecan
• Deruxtecan（DX-8951）
• N-((S)-10-Benzyl-1-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-1,6,9,12,15-pentaoxo-3-oxa-5,8,11,14-tetraazahexadecan-16-yl)-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamide
• Drug-Linker Conjugates for ADC,Inhibitor,inhibit,Deruxtecan
• Ibandronate Impurity 32
• N-[(S)-10-Benzyl-1-[[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-1,2,3,9,10,12,13,15-octahydrobenzo[de]pyrano[3’,4’:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1,6,9,12,15-pentaoxo-3-oxa-5,8,11,14-tetraazahexadecan-16-yl]-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamide
• MC-GGFG-Exetecan Deruxtecan analog
• N-((S)-10-Benzyl-1-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-1,6,9,12,15-pentaoxo-3-oxa-5,8,11,14-tetraazahexadecan-16-yl)-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamide
• N-[(S)-10-Benzyl-1-[[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-1,2,3,9,10,12,13,15-octahydrobenzo[de]pyrano[3’,4’:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1,6,9,12,15-pentaoxo-3-oxa-5,8,11,14-tetraazahexadecan-16-yl]-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamide
• 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-{[({[(1S)-1-[({[({[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,1?.0?,13.0?,11.02?,2?]tetracosa-1,6(11),12,14,16(24),17,19-heptaen-23-yl]carbamoyl}methoxy)methyl]carbamoyl}methyl)carbamoyl]-2-phenylethyl]carbamoyl}methyl)carbamoyl]methyl}hexanamide
• 1599440-13-7
• C52H56FN9O13
• Pharmaceutical
• API
• ADC